- Home
- AEMD vs TCRT Comparison
AEMD vs TCRT Comparison
Compare AEMD & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- TCRT
- Stock Information
- Founded
- AEMD 1984
- TCRT 1998
- Country
- AEMD United States
- TCRT United States
- Employees
- AEMD N/A
- TCRT N/A
- Industry
- AEMD Medical/Dental Instruments
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- TCRT Health Care
- Exchange
- AEMD Nasdaq
- TCRT Nasdaq
- Market Cap
- AEMD 4.1M
- TCRT 3.9M
- IPO Year
- AEMD N/A
- TCRT N/A
- Fundamental
- Price
- AEMD $1.14
- TCRT $2.25
- Analyst Decision
- AEMD Buy
- TCRT
- Analyst Count
- AEMD 2
- TCRT 0
- Target Price
- AEMD $28.75
- TCRT N/A
- AVG Volume (30 Days)
- AEMD 126.6K
- TCRT 44.8K
- Earning Date
- AEMD 08-13-2025
- TCRT 08-14-2025
- Dividend Yield
- AEMD N/A
- TCRT N/A
- EPS Growth
- AEMD N/A
- TCRT N/A
- EPS
- AEMD N/A
- TCRT N/A
- Revenue
- AEMD N/A
- TCRT $6,000.00
- Revenue This Year
- AEMD N/A
- TCRT $5,680,500.00
- Revenue Next Year
- AEMD N/A
- TCRT N/A
- P/E Ratio
- AEMD N/A
- TCRT N/A
- Revenue Growth
- AEMD N/A
- TCRT N/A
- 52 Week Low
- AEMD $1.09
- TCRT $1.31
- 52 Week High
- AEMD $8.44
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- AEMD 38.81
- TCRT 30.37
- Support Level
- AEMD $1.09
- TCRT $2.16
- Resistance Level
- AEMD $1.41
- TCRT $2.85
- Average True Range (ATR)
- AEMD 0.09
- TCRT 0.32
- MACD
- AEMD 0.02
- TCRT -0.03
- Stochastic Oscillator
- AEMD 15.62
- TCRT 9.09
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.